Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein
... in primary and metastatic melanoma
Recent publication
The chondroitin sulfate proteoglycan 4 is discussed as a possible target for new therapies in metastatic melanoma. At the University Hospital St. Pölten, the proteoglycan expression was investigated in 189 tissue samples from melanomas. The improved understanding of the role of chondroitin sulphate proteoglycan 4 in cancer helps to develop new therapeutic approaches. The study was funded by the NÖ Forschungs- und Bildungsges.m.b.H.. Results were published freely in the journal "Oncology Letters" thanks to KL's open-access funding.
Grossauer A, Uranowska K, Kitzwögerer M, Mostegel M, Breiteneder H, Hafner C. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma. Oncology Letters. 2023 Jul 20;26(3). doi: 10.3892/ol.2023.13968
Prim. Clin. Ass. Prof. Dr. Melitta Kitzwögerer
Institute of Clinical Pathology and Molecular Pathology of the Lower Austria Central Region (University Hospital St. Pölten)
PD Dr. Christine Hafner
Division of Dermatology and Venereal Diseases (University Hospital St. Pölten)
